---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044767"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:19:08.865326+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma reports positive Phase 3 etripamil data for PSVT self-treatment

## Summary
- NODE-303 open-label study: etripamil nasal spray restored sinus rhythm with median time-to-conversion 17.0 minutes.
- Efficacy at 30 min was 60%, at 60 min 69.9% — similar to prior double-blinded studies.
- Safety consistent: adverse events mostly localized to nasal administration site; frequency decreased with successive episodes.
- Data presented at ACC 2024 and published in JACC; supports potential shift in PSVT self-management.
- CARDAMYST (conditionally approved brand name) could become first at-the-ready option for acute PSVT if approved.

## SEC filing metadata
- accession: 0001104659-24-044767
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924044767/0001104659-24-044767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924044767/tm2411306d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044767
- JSON: https://secwatch.observer/filing/0001104659-24-044767.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.